Target intelligence / Profile preview

Pre-mRNA 3'-end-processing factor FIP1-like 1 (FIP1L1)

Target
FIP1L1
Molecular classification
Other: Pre-mRNA processing factor, RNA-binding protein, Component of the cleavage and polyadenylation specificity factor (CPSF) complex, Fusion protein (when fused to PDGFRA, becomes a constitutively active tyrosine kinase receptor)
01

Overview

Pre-mRNA 3'-end-processing factor FIP1-like 1 (FIP1L1) is a protein-coding subunit of the cleavage and polyadenylation specificity factor (CPSF) complex, essential for polyadenylation and processing of mRNA 3'-ends in eukaryotic cells. FIP1L1 recognizes polyadenylation sites and binds U-rich RNA sequences, stimulating poly(A) polymerase activity to stabilize mRNAs for export and translation. In humans, a chromosomal deletion at 4q12 can create a fusion gene (FIP1L1-PDGFRA), resulting in a constitutively active tyrosine kinase driving hypereosinophilic syndrome and chronic eosinophilic leukemia. Imatinib and other kinase inhibitors target the fusion protein in affected patients. FIP1L1 is frequently studied for its role in RNA processing, leukemogenesis via gene fusion, and as a diagnostic, therapeutic, and prognostic marker in selected hematological malignancies.

Other names
FIP1-like 1 proteinFIP1_HUMANFIP1hFip1RHEFactor interacting with PAPRearranged in hypereosinophilia
02

Mechanism of action

Tyrosine kinase inhibition: Drugs like imatinib inhibit the constitutively active tyrosine kinase activity of the FIP1L1-PDGFRA fusion protein, leading to reduced proliferation of leukemia cells.

03

Biological functions

Pre-mRNA 3'-end processingPolyadenylation site recognitionStimulates poly(A) polymerase activityRNA binding (U-rich elements)Tethering poly(A) polymerase to CPSF complex
04

Disease associations

Chronic eosinophilic leukemiaIdiopathic hypereosinophilic syndromeMyeloproliferative neoplasmsT-lymphoblastic leukemia/lymphoma
05

Safety considerations

Potential resistance to tyrosine kinase inhibitorsOff-target effects and myelosuppression with tyrosine kinase inhibitor therapyUnintended effects of abnormal mRNA processing due to FIP1L1 alterations
06

Interacting drugs

07

Biomarkers

FIP1L1-PDGFRA fusion geneIncreased eosinophils

Beyond the preview

Go deeper on Pre-mRNA 3'-end-processing factor FIP1-like 1 (FIP1L1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pre-mRNA 3'-end-processing factor FIP1-like 1 (FIP1L1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call